What is Monoclonal Antibody Therapy (MAT)?

The FDA has issued an emergency use authorization (EUA) for monoclonal antibody therapy (MAT) aimed at helping patients’ immune systems recognize and respond more effectively to the virus.

Monoclonal Therapy are laboratory-made antibodies that mimic a body’s immune response to infection. These antibodies are specific to the Coronavirus that causes COVID-19 and are designed to attach to the virus and prevent attachment and entry into cells. Preliminary data suggests that some outpatients may benefit from receiving monoclonal antibody therapy (MAT) early in the course of infection and may reduce the risk of disease progression and potential hospitalization.

Learn More About HCA’s Monoclonal Antibody Treatment Clinic in New Hampshire

HCA New Hampshire facilities – Frisbie Memorial Hospital, Parkland Medical Center, and Portsmouth Regional Hospital – are pleased to announce the availability of Monoclonal Antibody Infusion Therapy (MAT) for eligible COVID-19 positive patients. This advanced care is provided by Portsmouth Regional Hospital’s monoclonal antibody treatment clinic and is available to patients of HCA NH facilities, as well as to qualified COVID-19 patients regardless of a providers’ affiliation.

If a patient is having mild-to-moderate symptoms of COVID-19 confirmed by a positive test result and are at risk because of certain health conditions or older than 65, you may recommend that they receive Monoclonal Therapy.

Medication supply is limited and administered based upon availability. Patients must obtain a referral from their physician. Patients who meet the criteria for treatment will be referred for outpatient treatment at Portsmouth Regional Hospital infusion centers. Patients eligible for therapy will receive one dose by intravenous infusion over the course of one hour.